Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price was up 14% during mid-day trading on Monday after an insider bought additional shares in the company. The stock traded as high as $27.86 and last traded at $27.48, with a volume of 678,318 shares traded. The stock had previously closed at $24.10.

Specifically, Director Henrietta Fore bought 6,000 shares of the stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $23.99 per share, for a total transaction of $143,940.00. Following the completion of the purchase, the director now owns 24,000 shares in the company, valued at $575,760. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Rick E. Winningham bought 10,000 shares of the stock in a transaction dated Friday, August 11th. The stock was bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the purchase, the chief executive officer now owns 866,377 shares of the company’s stock, valued at approximately $21,226,236.50. The disclosure for this purchase can be found here. 6.10% of the stock is currently owned by company insiders.

A number of equities research analysts have recently issued reports on TBPH shares. Needham & Company LLC increased their target price on Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. BidaskClub lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, July 19th. Finally, Leerink Swann set a $47.00 target price on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, May 10th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $41.13.

The firm’s market capitalization is $1.48 billion. The firm’s 50 day moving average price is $35.41 and its 200 day moving average price is $35.50.

A number of large investors have recently modified their holdings of TBPH. BlackRock Inc. increased its stake in shares of Theravance Biopharma by 117,412.4% in the first quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock valued at $129,326,000 after buying an additional 3,509,456 shares during the period. MARSHALL WACE ASIA Ltd bought a new stake in shares of Theravance Biopharma during the first quarter valued at about $21,862,000. Marshall Wace North America L.P. bought a new stake in shares of Theravance Biopharma during the first quarter valued at about $21,862,000. Goldman Sachs Group Inc. increased its stake in shares of Theravance Biopharma by 341.2% in the first quarter. Goldman Sachs Group Inc. now owns 256,110 shares of the biopharmaceutical company’s stock valued at $9,430,000 after buying an additional 198,062 shares during the period. Finally, Woodford Investment Management Ltd increased its stake in shares of Theravance Biopharma by 1.9% in the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock valued at $393,948,000 after buying an additional 197,500 shares during the period. Hedge funds and other institutional investors own 82.77% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/15/theravance-biopharma-inc-nasdaqtbph-trading-up-14-after-insider-buying-activity.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Receive News & Stock Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related stocks with our FREE daily email newsletter.